This content is from: Premium

RA Capital’s Big Covid Bet

The biopharma specialist recently invested $200 million in a company developing a vaccine and is raising money for a new blank-check company.

Little-known health care hedge fund firm RA Capital Management raised its profile Monday when it shelled out $200 million to invest in Novavax, a late-stage biotechnology company developing a vaccine for Covid-19. RA Capital bought Series A convertible preferred stock, convertible into nearly 4.4 million common shares, according to the announcement.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content